ZappRX gets $25 million from Chinese VC’s to expand into the U.S. drug prescription market

 ZappRX, the app that aims to make it easier to manage specialty drug prescriptions, has pulled in $25 million in Series B funding led by Qiming US, the Chinese venture outfit’s stateside health care fund. GV (formerly Google Ventures) and GlaxoSmithKline’s funding arm SR One were also in the round and GV’s Krishna Yeshwant and Qiming US’s Mark McDade will now join… Read More

from TechCrunch